Our Partners
Expertise Partners:
Almac Clinical Services
Almac Clinical Services dedicated Unlicensed Medicine Services group currently manage over 200+ active Managed Access programs, delivering critical medication to patients across 80 countries worldwide. From forecasting and production through to storage and distribution, Almac provides the global reach, expert people, validated processes, and cutting edge technology to empower sponsors to maintain ethical, compliant, and cost- effective access to unlicensed treatments.
Early Access Care
Early Access Care is a full-scale specialist service provider of Compassionate Use and Named Patient Programs, ranging from programme planning, protocol development, end-to-end operational management, Real World Data services, and a variety of customized service offerings. We work with biotech and pharmaceutical companies to set up and manage programs in the pre and post-approval space, including post-trial access, managing all regulatory and logistical aspects of early access. Speak with one of our representatives at the EAC booth to find out more about how our service and staff may support your plans.
Inceptua Early Access
Early Access Care is a full-scale specialist service provider of Compassionate Use and Named Patient Programs, ranging from programme planning, protocol development, end-to-end operational management, Real World Data services, and a variety of customized service offerings. We work with biotech and pharmaceutical companies to set up and manage programs in the pre and post-approval space, including post-trial access, managing all regulatory and logistical aspects of early access. Speak with one of our representatives at the EAC booth to find out more about how our service and staff may support your plans.
WEP
At WEP, we are With Every Patient, as we believe every patient should have access to treatment! We operate as a Pharma Services Provider (PSP) that is committed to providing Drug Development and Treatment Access Solutions for patients worldwide. We specialize in Expanded Access Programs (EAPs) and help Sponsors deliver value-driven EAPs that are designed and fit
around their specific needs and development pipeline. Our programs are delivered through High Quality, High Service, and High Value, returning a positive ROI to all Sponsors we have partnered with.
Hosting Partners:
BAP Pharma
BAP Pharma is an award-winning, responsive and cost-effective medicines access solutions partner, specialising in providing tailored access solutions to health care professionals and patients. Our experts in Early and Managed Access Programs (EAP/MAP) can assist and support your efforts to bring critical treatments to patients in need, ensuring they get the medicines they need, when they need them, anywhere in the world.
Bionical Emas
Bionical Emas is a global Contract Research Organization (CRO) combining Clinical Development, Clinical Trial Supply (CTS) and Early Access Programs (EAP) bringing lifechanging medicines to patients around the world. Their unique integrated business model, with its range of services and capabilities, benefit many of the world’s leading pharma and biotech companies. This distinctive offering enables them to maximize access and generate evidence at every stage of the drug development pathway. Early Access Programs (often called Expanded Access, Pre-approval Access, Compassionate Use, Named Patient or Managed Access Programs) deliver potentially lifesaving treatments to patients around the world while adding true value to clients through a range of additional cutting-edge services. Bionical Emas are the only specialist Early Access Program (EAP) partner to harness the full power of an established and successful Contract Research Organization. Their global EAP experience in oncology and rare disease areas is perfectly complemented by a range of in-house services.
myTomorrows
myTomorrows is a global health tech company dedicated to helping patients and physicians discover and access treatment options. We’ve partnered with 50+ BioPharma companies to support global expanded access programs, gather invaluable real-world data, and streamline patient recruitment for clinical trials. We are experts in the field of expanded access, having gained
experience over a decade, and we manage all aspects of expanded access - from regulatory strategy program setup to full operational execution. We distinguish ourselves by taking a proactive stakeholder-focused approach.
Event Partners:
MedaSystems
MedaSystems' software is trusted by pharmaceutical companies across the United States and Europe to enhance patient outcomes and streamline the management of drugs under various pre-approval access pathways. Numerous major academic institutions actively use it, and our research and development efforts are grounded in thousands of hours spent collaborating with experts in global pre-approval access.
Life Science Companies use MedaSystems to:
- Easily collaborate with healthcare providers
- Make approval decisions faster
- Reduce frustrating repetitive manual steps
- Capture real-world data
- Comply with regulations
Cisiv
Cisiv is an innovative technology company providing software that supports the pharmaceutical industry in its work with licensed medicines and medicines distributed through MAPs. Our cutting-edge platform, Baseline Plus, is an integrated solution including Managed Access, Safety Reporting, Real World Data capture, eConsent, ePro and surveys. It has been used for over 10 years by leading global companies in extensive, international MAPs, prospective observational studies and combined activities where RWD is collected with a MAP.
Baseline Plus is compliant with all applicable global requirements including 21 CFR Part 11, GCP, GDPR, and HIPAA and. Our MAP platform enables streamlined request management, controlled approval processes and a unified experience for HCPs and pharmacists through highly configurable role-based workflows. Cisiv’s mission is to provide technology to support pharmaceutical companies with the process and data capture that bring medicines closer to patients.
